The University of Wisconsin-Madison agreed to license its patents for human embryonic stem cells to Pfizer for drug development. "Stem cells can be used to create specialized human tissue," a Pfizer official said. "Our scientists will determine how new medicines may be able to improve the way stem cells regenerate damaged tissues. We will be optimizing the production of cells that could, one day, be used for therapeutic purposes."
Published in Brief: